Clinical results analyze dexamethasone implant effect on macular thickness

Video
Conference|ARVO

Dr. Daniel F. Kiernan discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.

Dr. Daniel F. Kiernan, a vitreoretinal surgeon at The Eye Associates, Sarasota, Florida, discusses the highlights of his 2021 ARVO virtual presentation on the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on optical coherence tomography (OCT) testing following vitreoretinal surgery.

See more ARVO coverage

Recent Videos
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
At EURETINA 2024, Martin S. Zinkernagel, MD, PhD, on the future of real-world AI use
Alexandra Miere, MD, PhD, Associate Professor of Ophthalmology, University Paris Est Créteil, France, speaks at EURETINA
Related Content
Ocuphire Pharma and Opus Genetics announce merger

Ocuphire Pharma and Opus Genetics announce merger

David Hutton
October 22nd 2024
Article

The company also announced it will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for the treatment of non-proliferative diabetic retinopathy.

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A black box in a dark room is opened slightly. The lid is displaced and a red light glows inside. Image credit: ©alastis – stock.adobe.com

The “black box” of artificial intelligence in ophthalmology

Johan Blanckaert, MD
October 7th 2024
Article

Making the most of AI means letting go of fear, says Editorial Advisory Board member Johan Blanckaert, MD

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A cup of coffee and a pair of glasses sit on a desk, alongside a keyboard and notebook. Image credit: ©karandaev – stock.adobe.com

Study: Oral caffeine intake increases inner electro-retinal activity in young adults

Lynda Charters
October 3rd 2024
Article

Investigators studied global-flash multifocal electroretinogram responses

Image credit: ©Who is Danny – stock.adobe.com

What's missing in patient education?

Albert J. Augustin, MD
October 3rd 2024
Article

A different approach better serves patients with diabetic retinopathy

© 2024 MJH Life Sciences

All rights reserved.